Innoplexus
Innoplexus, founded in 2015 and headquartered in Eschborn, Germany, specializes in AI-driven solutions for drug discovery and development, employing over 250 people and holding more than 120 patent applications in AI, machine learning, and blockchain technologies.
Company History
Innoplexus was founded in 2015 and has its headquarters in Eschborn, Germany. The company also operates offices in Pune, India, and Iselin, United States. As of now, Innoplexus employs over 250 people and focuses on developing AI-driven solutions for drug discovery and development.
Patents and Technological Innovations
Innoplexus holds over 120 patent applications, with more than 60 grants in the fields of artificial intelligence, machine learning, and blockchain technologies. These patents reflect the company’s ongoing commitment to pioneering technological advancements that support their wide range of data-driven solutions in the healthcare and pharmaceutical sectors.
AI-Driven Solutions for Drug Discovery
Innoplexus provides advanced AI-driven solutions specifically designed for drug discovery and development. The company’s proprietary technology, including Life Science Language Processing™ and Computer Vision, plays a crucial role in contextualizing multimodal data, allowing for comprehensive analysis of data from diversified sources.
Ontosight® Platform
The Ontosight® platform is a key innovation by Innoplexus that supports all stages of drug development, from ideation to market. This platform generates real-time insights from both structured and unstructured private and public data sources, providing invaluable support throughout the drug development lifecycle.
Notable Achievements
Innoplexus has been recognized for its contributions to digital innovation, demonstrated by winning the Horizon Interactive Gold Award for the Curia app. This award underscores the company's expertise and commitment to utilizing cutting-edge technology to advance drug discovery and development.